Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative GroupAnna Sureda, E. Condé, José García‐Laraña et al.|Journal of Clinical Oncology|2001Cited by 233
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapseAnna Sureda, E. Condé, M. Constans et al.|Annals of Oncology|2005Cited by 220
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?Jesús F. San Miguel, J Díaz-Mediavilla, Juan José Lahuerta et al.|The Hematology Journal|2000Cited by 117
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, M.V. Mateos, Joaquín Martínez‐López et al.|Haematologica|2010Cited by 113
Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish RegistryAdrían Alegre, J Díaz-Mediavilla, Jesús F. San Miguel et al.|Bone Marrow Transplantation|1998Cited by 85